Results 51 to 60 of about 9,825 (155)
Mediterranean Journal of Hematology and Infectious Diseases, 2019 Background: Hepatitis C virus (HCV) infection is a public health problem. Such an infection is prevalent and aggressive in patients with end-stage kidney disease (ESKD).
Nawfal R Hussein, Zana Saleem, Kais Abd
doaj +1 more source
Egyptian Journal of Chest Disease and Tuberculosis, 2020 Background To date, no sufficient reports have studied the effects of sofosbuvir-based hepatitis C virus (HCV) treatment regimens on chronic obstructive pulmonary disease(COPD) exacerbation.
Ahmad Abbas +3 more
doaj +1 more source
Canadian Journal of Gastroenterology and Hepatology, 2016 Background and Aim. This is an open label prospective cohort study conducted at a tertiary care hospital. The primary endpoint is SVR12 in patients treated with sofosbuvir-based therapy in post-liver transplant patients with genotype 4 HCV recurrence ...
A. Ajlan +8 more
doaj +1 more source
Molecules, 2020 A simple, rapid, sensitive, and precise reversed-phase liquid chromatographic method was developed and validated for the simultaneous determination of four direct-acting antivirals, sofosbuvir (SF), ledipasvir (LD), declatasvir (DC), and simeprevir (SM),
Essam Ezzeldin +5 more
doaj +1 more source
HCV‐Specific T‐Cell Recovery After a Year of SVR Following DAA Therapy
Journal of Medical Virology, Volume 98, Issue 8, August 2026.ABSTRACT Direct‐acting antiviral (DAA) drugs lead to sustained virologic response (SVR) in almost all treated patients with chronic hepatitis C virus (HCV) infection. Despite this success, the long‐term effects of HCV clearance by DAA therapy on T‐cell‐mediated antiviral immunity remain unclear, particularly concerning the restoration of immune ...
Tetiana Pozniak +9 more
wiley +1 more source
Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C
Infection and Drug Resistance, 2019 Lindsey M Childs-Kean, Natalie A Brumwell, Emma F LodlDepartment of Pharmacotherapy and Translational Research, University of Florida College of Pharmacy, Gainesville, FL, USAAbstract: The treatment of chronic hepatitis C has been revolutionized with the
Childs-Kean LM, Brumwell NA, Lodl EF
doaj
Gut and Liver, 2020 Background/Aims: Sofosbuvir (SOF)-based therapy has been used in Korean patients with chronic hepatitis C virus (HCV) infection since January 2016. This study aimed to investigate the real-life effectiveness and safety of SOF-based therapy in genotype 2 ...
Eun Sun Jang +7 more
doaj +1 more source
The American Journal on Addictions, Volume 35, Issue 4, Page 534-542, July 2026.Abstract Background and Objectives Injection drug use is a driver of hepatitis C virus (HCV) transmission, thus integrating HCV care into addiction care is likely necessary for HCV elimination. Here we describe how we integrated HCV care into our addiction medicine (AM) clinic and evaluate its effect on HCV treatment.
Arya Zandvakili +11 more
wiley +1 more source
Advancing Antiviral Design: Integrating Natural Products, Computation and Targeted Delivery
Chemical Biology &Drug Design, Volume 108, Issue 1, July 2026.A stepwise translational framework linking natural‐product discovery, computational prioritisation, experimental validation, lead optimisation and targeted delivery is proposed to advance antiviral design. ABSTRACT The COVID‐19 pandemic highlighted the role of rapid viral mutation and global connectivity in accelerating viral emergence and spread ...
Adedayo Ayodeji Lanrewaju +3 more
wiley +1 more source